Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sucampo Pharmaceuticals SCMP

Healthcare Drug Manufacturers - Specialty & Generic
"Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development... see more

Recent & Breaking News (NDAQ:SCMP)

Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone

GlobeNewswire August 21, 2014

Sucampo Reports Second Quarter 2014 Financial Results and Corporate Update

GlobeNewswire August 5, 2014

Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone)

GlobeNewswire July 23, 2014

Sucampo Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results and Corporate Update Teleconference and Webcast on August 5

GlobeNewswire July 22, 2014

Swissmedic Approves AMITIZA(R) (Lubiprostone) for the Treatment of Opioid-Induced Constipation

GlobeNewswire July 7, 2014

AMITIZA(R) (Lubiprostone) Receives NICE Recommendation

GlobeNewswire June 17, 2014

Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's Vote

GlobeNewswire June 12, 2014

Sucampo Announces Webcast of Its Presentation at 2014 Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2014

Sucampo Announces Webcast of Its Presentation at the 2014 UBS Global Healthcare Conference

GlobeNewswire May 13, 2014

Sucampo Pharmaceuticals, Inc., Reports First Quarter 2014 Financial and Operating Results

GlobeNewswire May 7, 2014

Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal

GlobeNewswire May 6, 2014

Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences

GlobeNewswire May 1, 2014

Sucampo Pharmaceuticals Announces First Quarter 2014 Results and Operating Highlights Teleconference and Webcast

GlobeNewswire April 30, 2014

Preclinical Data for Lubiprostone and Unoprostone Isopropyl to be Presented at Experimental Biology Conference 2014

GlobeNewswire April 25, 2014

VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer

PR Newswire March 25, 2014

Sucampo Co-Founder and Chairman Emeritus, Dr. Ryuji Ueno, to Receive Visionary Award From the Foundation Fighting Blindness

GlobeNewswire March 25, 2014

Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)

GlobeNewswire March 14, 2014

Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.

Thomson Reuters ONE March 12, 2014

Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.

GlobeNewswire March 12, 2014

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 ROTH Conference

GlobeNewswire March 5, 2014